Qualigen-Logo-Tag.png
Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex
02 juin 2022 09h00 HE | Qualigen Therapeutics, Inc.
Transaction expected to significantly advance commercial readiness of NanoSynex’s innovative diagnostics technology platform focused on the $30+ Billion global infectious disease testing market ...
Qualigen-Logo-Tag.png
Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting
26 mai 2022 09h15 HE | Qualigen Therapeutics, Inc.
Abstracts Highlight In Vitro and In Vivo Activity of Qualigen’s Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath Tumors CARLSBAD, Calif., May 26, 2022 (GLOBE...
Qualigen-Logo-Tag.png
Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program
15 mars 2022 09h15 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen-Logo-Tag.png
Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders
22 févr. 2022 09h15 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen-Logo-Tag.png
Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results
17 août 2021 08h00 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif.,, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces its intention to prioritize its focus to its oncology pipeline that includes QN-247...